Linked Life Data

18467593

Source:http://linkedlifedata.com/resource/pubmed/id/18467593

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-7-21
pubmed:abstractText
Arginine vasopressin (AVP) plays an important role in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). The present study evaluated the acute and chronic effects of vasopressin V(1a) receptor subtype (V(1a)) and vasopressin V(2) receptor subtype (V(2)) antagonists on renal function and cardiac hypertrophy in rats with CHF. The effects of acute administration of SR 49059 [(2S)1-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-1-(3,4-dimethoxybenzene-sulfonyl)-3-hydroxy-2,3-dihydro-1H-indole-2-carbonyl]-pyrrolidine-2-carboxamide)] (0.1 mg/kg) and SR 121463B (1-[4-(N-tert-butylcarbamoyl)-2-methoxybenzenesulfonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)cyclohexane]indol-2-one, fumarate; equatorial isomer) (0.3 mg/kg), V(1a) and V(2) antagonists, respectively, on renal function, and of chronic treatment (3.0 mg/kg/day for 7 or 28 days, via osmotic minipumps or p.o.), on water excretion and cardiac hypertrophy were studied in rats with aortocaval fistula and control rats. CHF induction increased plasma AVP (12.8 +/- 2.5 versus 32.2 +/- 8.3 pg/ml, p < 0.05). Intravenous bolus injection of SR 121463B to controls produced dramatic diuretic response (from 5.5 +/- 0.8 to 86.3 +/- 21.9 microl/min; p < 0.01). In contrast, administration of SR 49059 did not affect urine flow. Likewise, administration of SR 121463B, but not SR 49059, to rats with CHF significantly increased urinary flow rate from 20.8 +/- 6.4 to 91.6 +/- 26.5 microl/min (p < 0.01). The diuretic effects of SR 121463B were associated with a significant decline in urinary osmolality and insignificant change of Na+ excretion. In line with its acute effects, chronic administration of SR 121463B to CHF rats increased daily urinary volume 2 to 5-fold throughout the treatment period. Both SR 121463B and SR 49059 significantly reduced heart weight in CHF rats when administered for 4 weeks, but not 1 week. These results suggest that V(2) and V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1521-0103
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
326
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
414-22
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:18467593-Animals, pubmed-meshheading:18467593-Body Weight, pubmed-meshheading:18467593-Cardiomegaly, pubmed-meshheading:18467593-Disease Models, Animal, pubmed-meshheading:18467593-Diuresis, pubmed-meshheading:18467593-Drug Administration Schedule, pubmed-meshheading:18467593-Heart Failure, pubmed-meshheading:18467593-Indoles, pubmed-meshheading:18467593-Kidney Function Tests, pubmed-meshheading:18467593-Male, pubmed-meshheading:18467593-Morpholines, pubmed-meshheading:18467593-Organ Size, pubmed-meshheading:18467593-Osmolar Concentration, pubmed-meshheading:18467593-Pyrrolidines, pubmed-meshheading:18467593-Rats, pubmed-meshheading:18467593-Rats, Sprague-Dawley, pubmed-meshheading:18467593-Receptors, Vasopressin, pubmed-meshheading:18467593-Sodium, pubmed-meshheading:18467593-Spiro Compounds, pubmed-meshheading:18467593-Vasoconstriction
pubmed:year
2008
pubmed:articleTitle
Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
pubmed:affiliation
General Surgery, Rambam Medical Center, Haifa, Israel.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't